Lonapegsomatropin + Somatropin
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Turner Syndrome
Conditions
Turner Syndrome
Trial Timeline
Feb 15, 2023 → Dec 1, 2027
NCT ID
NCT05690386About Lonapegsomatropin + Somatropin
Lonapegsomatropin + Somatropin is a phase 2 stage product being developed by Ascendis Pharma for Turner Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT05690386. Target conditions include Turner Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05690386 | Phase 2 | Active |
| NCT04615273 | Phase 3 | Completed |
Competing Products
10 competing products in Turner Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Somatropin | Eli Lilly | Phase 3 | 77 |
| Humatrope | Eli Lilly | Approved | 85 |
| 17 beta estradiol | Eli Lilly | Phase 3 | 77 |
| Somatropin + Ethinyl estradiol + Medroxyprogesterone acetate | Eli Lilly | Phase 3 | 77 |
| r-hGH | Merck | Approved | 85 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 3 | 76 |
| estradiol | Novo Nordisk | Approved | 84 |
| Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch | Novo Nordisk | Phase 1 | 32 |
| somatotropin | Pfizer | Pre-clinical | 22 |
| Somatropin (rDNA origin) | Ipsen | Phase 3 | 74 |